Update in Endocrinology
Authors: Janet A. Schlechte
Journal: Annals of Internal Medicine (1998)

Updates1 November 1998Update in EndocrinologyJanet A. Schlechte, MD and Robert Kreisberg, MDJanet A. Schlechte, MD1998-99 Series: John Roberts, MD, EditorFrom University of Iowa, Iowa City, Iowa; and Baptist Health Center, Birmingham, Alabama.Search for more papers by this author and Robert Kreisberg, MD1998-99 Series: John Roberts, MD, EditorFrom University of Iowa, Iowa City, Iowa; and Baptist Health Center, Birmingham, Alabama.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-9-199811010-00008 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Important advances in endocrinology that were reported during the past year focused on five major areas: osteoporosis and calcium, diagnostic testing and treatment of thyroid disease, prolactinomas, groups that may benefit from lipid-lowering drugs, and a redefinition of diabetes mellitus.Osteoporosis and CalciumA bisphosphonate drug was shown to help prevent fractures in some persons taking high-dose prednisone for at least 1 year. A selective estrogen receptor modulator, raloxifene, was shown to favorably alter several markers of complications of the postmenopausal state without increasing the risk for breast cancer. Finally, the incidence of primary hyperparathyroidism has decreased dramatically since 1975, ...References1. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998; 279:1445-51. Google Scholar2. Schneider AB, Gierlowski T, Shore-Freedman E, Stovall M, Ron E, Lubin J. Dose-response relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab. 1995; 80:254-7. Google Scholar3. Fujiwara S, Sposto R, Ezaki H, Akiba S, Neriishi K, Kodama K, et al. Hyperparathyroidism among atomic bomb survivors in Hiroshima. Radiat Res. 1992; 130:372-8. Google Scholar4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Scandinavian Simvastatin Survival Study Group. Lancet. 1994; 344:1383-9. Google Scholar Author, Article, and Disclosure InformationAffiliations: 1998-99 Series: John Roberts, MD, EditorFrom University of Iowa, Iowa City, Iowa; and Baptist Health Center, Birmingham, Alabama.Corresponding Author: Janet A. Schlechte, MD, University of Iowa Clinical Research Center, Room 157 MRF, 200 Hawkins Drive, Iowa City, IA 52242.Current Author Addresses: Dr. Schlechte: University of Iowa Clinical Research Center, Room 157 MRF, 200 Hawkins Drive, Iowa City, IA 52242. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUpdate in Endocrinology Hunter Heath III , Bruce Mitlak , and Pamela Anderson Update in Endocrinology Janet A. Schlechte Metrics Cited byProtocolo diagnóstico y terapéutico de la hiperprolactinemiaUpdate in EndocrinologyHunter Heath III, MD, Bruce Mitlak, MD, and Pamela Anderson, MDEffects of Gemfibrozil on Lipid and Hemostatic Factors in Capd Patients 1 November 1998Volume 129, Issue 9Page: 719-725KeywordsBone densityCalciumCholesterolHyperparathyroidismInsulinOsteoporosisStable coronary artery diseaseStrokeThyroidUltrasound imaging Issue Published: 1 November 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...